Oncolytics Biotech (Oncolytics Biotech) ROE % Adjusted to Book Value : -11.47% (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech ROE % Adjusted to Book Value?

Oncolytics Biotech's ROE % for the quarter that ended in Dec. 2023 was -56.09%. Oncolytics Biotech's PB Ratio for the quarter that ended in Dec. 2023 was 4.89. Oncolytics Biotech's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -11.47%.

Oncolytics Biotech ROE % Adjusted to Book Value Historical Data

The historical data trend for Oncolytics Biotech's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech ROE % Adjusted to Book Value Chart

Oncolytics Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-32.15

-31.91

-14.94

-21.12

Oncolytics Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-24.07	-24.06	-12.35	-20.57	-11.47

Competitive Comparison of Oncolytics Biotech's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Oncolytics Biotech's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncolytics Biotech's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's ROE % Adjusted to Book Value falls into.

Oncolytics Biotech ROE % Adjusted to Book Value Calculation

Oncolytics Biotech's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-103.29%	/	4.89
	=	-21.12%

Oncolytics Biotech's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-56.09%	/	4.89
	=	-11.47%

Oncolytics Biotech ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncolytics Biotech (Oncolytics Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

ONC:Canada

Address

322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5

Website

https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.